Indian researchers have unveiled a groundbreaking nanoformulation designed to enhance the safety and effectiveness of Parkinson’s disease treatment. This is reported by
IANS, a partner of TV BRICS.
The group of scientists has developed a targeted drug delivery system that enables the sustained release of 17β-oestradiol (E2), a hormone essential for managing Parkinson’s symptoms.
Parkinson’s disease, a progressive neurodegenerative disorder, is linked to an imbalance of 17β-oestradiol in the brain. However, the widespread use of this hormone in therapy has been limited due to its potential side effects and an incomplete understanding of its molecular mechanisms. To address these challenges, researchers have utilised dopamine receptor D3 (DRD3)-conjugated chitosan nanoparticles to precisely deliver 17β-oestradiol to the brain, significantly improving its therapeutic potential.
This innovative nanoformulation prevents mitochondrial damage by inhibiting the translocation of calpain.
The study further revealed a breakthrough in understanding the role of BMI1, a key regulator of mitochondrial homeostasis, in Parkinson’s disease, the source claims. The nanoformulation successfully restored BMI1 expression by preventing its degradation through calpain inhibition, highlighting a new potential target for neuroprotective therapies.
Photo:
iStock
